Patisiran is beneficial for the treatment of TTR cardiac amyloidosis

Nature Reviews Cardiology, Published online: 06 November 2023; doi:10.1038/s41569-023-00955-2Treatment with the small interfering RNA patisiran preserves functional capacity and improves health status and quality of life in patients with transthyretin cardiac amyloidosis, according to data from the 12-month double-blind period of the ongoing APOLLO-B trial.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research